GEN Exclusives

More »

GEN News Highlights

More »
Jul 1, 2008

Elixir Signs License Agreement with Boston University for Use of SIRT1 Modulators

  • Elixir Pharmaceuticals gained an exclusive license to Boston University’s intellectual property covering the use of modulators of SIRT1, a member of the sirtuin class of protein deacetylase enzymes.

    SIRT is a class of seven naturally occurring human enzymes, known to affect the storage and use of energy in cells. SIRT1 is the human equivalent of Sir2, a gene identified in yeast that has been recognized to play a key role in the control of lifespan, metabolism, resistance to stress, and other cellular regulatory pathways.

    The arrangement with Boston University encompasses therapeutic applications for SIRT1 modulators in metabolic diseases and modulation of SIRT1 for antiangiogenic activity to treat cancer.



Jobs

GEN Jobs powered by HireLifeScience.com connects you directly to employers in pharma, biotech, and the life sciences. View 40 to 50 fresh job postings daily or search for employment opportunities including those in R&D, clinical research, QA/QC, biomanufacturing, and regulatory affairs.
 Searching...
More »

GEN Poll

More » Poll Results »

New Drugs for Ebola

Do you think that biopharma companies should not have to go through the normal drug approval process in order to get potential life-saving therapies to Ebola patients more quickly?